CO.20 AND CO.17 TRANSLATIONAL RESEARCH: LOW-FREQUENCY KRAS MUTATIONS AS A PREDICTIVE BIOMARKER FOR CETUXIMAB RESISTANCE (THE “KRAS PROJECT”)